Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5701–5750 of 18644
On January 31, 2024, Rhinebeck Bancorp, Inc. (the “Company”), the holding company of Rhinebeck Bank, announced the retirement of Michael J. McDermott, Chief Financial Officer of the Company.
The current Vice President and Controller of the Company, Phillip Lekanides, has been named Interim Principal Financial and Accounting Officer effective June 1, 2024, and will manage the responsibilities of the principal financial and accounting officer in addition to his current responsibilities until a permanent replacement is named.
reporting that Johannes Cornelis Maria van Gaalen will cease to serve as Chief Financial Officer concurrently with Michael Beer assuming the position of Chief Financial Officer on April 15, 2024.
reporting that Johannes Cornelis Maria van Gaalen will cease to serve as Chief Financial Officer concurrently with Michael Beer assuming the position of Chief Financial Officer on April 15, 2024.
appointed Gustavo Garavaglia as Vice President and Chief Financial Officer of IPALCO and AES Indiana and to the Board of Directors of AES Indiana.
Eric Esser, who had been serving as the Company's President and Chief Operating Officer, assumed the position of President and CEO for the Company, effective as of April 16, 2024
Todd R. Nelson, Ph.D., Founder, Chief Executive Officer (CEO) of the Company and member of the Company’s Board of Directors (the Board), will cease serving as the Company's CEO, effective as of April 16, 2024, and will remain a member of the Board
on March 28, 2024, the Company received a notice from Steven Norman (“Mr. Norman”), who served as a director and the Chief Financial Officer (the “CFO”) of the Company, of his decision to resign as the CFO of the Company and as a member of the Board and all committees thereof, effective on March 28, 2024.
On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.
On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.
On April 17, 2024, Phoenix Motor Inc. (the “Company”) appointed Michael Yung as the Company’s Chief Financial Officer, effective immediately.
In connection with the Transactions, effective as of the Closing Date, Jacqueline Hernández, age 58, was appointed as MediaCo’s Interim Chief Executive Officer.
On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.
On April 12, 2024, New York Community Bancorp, Inc. (“NYCB” or the “Company”) announced that Craig Gifford was appointed as Senior Executive Vice President and Chief Financial Officer of the Company and Flagstar Bank, N.A., a wholly owned subsidiary of the Company (the “ Bank ”), effective immediately.
Mr. Gifford succeeds John J. Pinto, who ceased serving as Senior Executive Vice President and Chief Financial Officer of the Company and the Bank on April 12, 2024.
On April 12, 2024, the Company announced that Scott Shepherd was appointed as Senior Executive Vice President and Head of Commercial Real Estate of the Company and the Bank, effective immediately.
On April 15, 2024, Mr. Kenneth S. Wilson, Chief Executive Officer and Director of Jabil Inc. (the “Company”), was placed on a paid leave pending completion of an investigation related to corporate policies.
Effective as of April 19, 2024, the Company’s Board of Directors appointed Mr. Michael Dastoor, Chief Financial Officer, to serve as the Company’s interim Chief Executive Officer.
the Board of Directors of the Company appointed Ashford’s current Senior Vice President of Corporate Finance & Strategy, Stephen Zsigray, to fill the role of President and Chief Executive Officer at the Company, effective June 30, 2024.
Mr. Hay’s resignation is expected to be effective June 30, 2024.
Raymond Stachowiak, who has served as the Executive Chairman of the Board since March 7, 2023, was appointed as Chief Executive Officer in addition to continuing to serve as the Company’s Executive Chairman of the Board.
After the recent passing of Peter Gaccione, who served as the Chief Executive Officer of American Shared Hospital Services (the “ Company ”), on April 16, 2024,
Effective as of April 15, 2024, Mr. Grant Begley ceased to serve as the Interim Chief Executive Officer of the Company
setting forth the terms of Bill Irby’s appointment as Chief Executive Officer and Director of the Company effective as of April 15, 2024.
immediately following the Effective Time, the officers of the Company became: (i) Jeremy Davey as Chairman of the Board of Directors and Chief Executive Officer
On April 15, 2024, the Board of Directors (“Board”) appointed David Edmunds as Chief Financial Officer, effective immediately (the “Effective Date”).
Dr. Stacy Lindborg, the Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of her intent to resign from her current role at the Company, effective as of May 9, 2024.
Suzanne Foster, age 54, has been appointed to serve as the Chief Executive Officer of the Company, effective May 20, 2024.
the Board appointed Matthew D. Preston, the Company’s Chief Financial Officer, as acting principal executive officer of the Company.
granted Robert P. Jornayvaz III, Executive Chairman of the Board and Chief Executive Officer of the Company, a temporary medical leave of absence, effective immediately
and Alexander J. Jessett from Executive Vice President-Chief Financial Officer to President and Chief Financial Officer.
On March 15, 2024, the Former Board appointed Llewellyn Farquharson, the then Chief Financial Officer of the Company, as Chief Executive Officer and director of the Company, in order to fill the vacancy created by the CEO Resignation (the “ Interim CEO Appointment ”).
On April 12, 2024, the board of directors (the “ Board ”) of the Company held a special meeting (the “ Meeting ”) during which the Board ratified Mr. Farquharson’s Termination and appointed Spyridon Bonatsos as Chief Executive Officer and director of the Company
the Board ratified Mr. Farquharson’s Termination and appointed Spyridon Bonatsos as Chief Executive Officer and director of the Company
Also on March 15, 2024, to fill the vacancy in the Former Board created by the Interim CEO Appointment, the Former Board appointed Henry Bruce as Chief Financial Officer and director of the Company.
In early March of 2024, Paul Davis presented to the then current members of the board of directors (the “ Former Board ”) of Zalatoris II Acquisition Corp, a Nasdaq-listed exempted company formed in the Cayman Islands (the “ Company ”) a resignation letter resigning from his position as Chief Executive Officer and as a member of the Former Board (the “ CEO Resignation ”).
In early March of 2024, Paul Davis presented to the then current members of the board of directors (the “ Former Board ”) of Zalatoris Acquisition Corp., a Delaware corporation (the “ Company ”) a resignation letter resigning from his position as Chief Executive Officer and as a member of the Former Board
On March 15, 2024, the Former Board appointed Stephanos Papadopoulos, a then independent director of the Company, as Chief Executive Officer and director of the Company, in order to fill the vacancy created by the CEO Resignation (the “ New CEO Appointment ”).
Mr. Berenbaum succeeds Greg Cameron whose departure was previously announced and who will leave the Company in mid-May 2024.
On April 17, 2024, Bloom Energy Corporation (the "Company" or "Bloom") issued a press release announcing that Daniel Berenbaum has been appointed to serve as the Company’s Chief Financial Officer effective as of April 29, 2024.
On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company’s Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.
On April 10, 2024, Omega Therapeutics, Inc. (the “Company”) and Joshua Reed, the Company’s Chief Financial Officer, agreed to terminate his employment effective as of May 31, 2024
On April 11, 2024, Phoenix Motor Inc. (the “Company”) appointed Lewis W. Liu as the Company’s Chief Financial Officer, effective immediately.
Gov. Benson will resign as Interim Chief Executive Officer as of the Effective Date, but will continue to serve as a member of the Board.
On April 16, 2024, Planet Fitness, Inc. (the “Company”) announced the appointment of Colleen Keating, age 55, as Chief Executive Officer (“CEO”) of the Company, effective June 10, 2024 ( the “Effective Date”).
The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).
pursuant to which Dr. Forssell was discharged from his position as the Company’s President and CEO and will act as a Senior Advisor to the management team of NeoNode Technologies AB, the Company’s subsidiary, and the Board until December 31, 2024.
On April 16, 2024, James W. Tivy resigned from his position of Chief Financial Officer of M-tron Industries, Inc. ("M-tron", "MPTI", or the "Company"), effective immediately.
on April 16, 2024, the Board of Directors of the Company, by unanimous written consent, appointed Linda Biles, age 62, currently M-tron's Vice President and Controller, as Executive Vice President – Finance and as principal financial officer.
Mr. Tivy resigned as Chief Accounting Officer and principal financial officer effective April 16, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.